Publication date: Jul 11, 2025
We analyze COVID19 pandemia and shortage of verteporfin (Visudyne(R)) consequences in photodynamic therapy (PDT) treated patients. A retrospective study was performed in 97 patients treated with PDT last 3 years. We used HALF DOSE PDT for chronic central serous chorioretinopathy (cCSCR) (n=84) and FULL DOSE for polypoidal choroidal vasculopathy (PCV) (n=13). We evaluated changes in visual acuity (VA) and resolution of subretinal fluid (SRF) by optical coherence tomography (OCT), assessing the number of retreatments. The mean referral delay time was 28. 5 +/- 6. 24 months. 53. 6% of cCSCR and 75% of PCV patients received previous treatments. An improvement in VA was observed in cCSCR patients after treatment, while PCV patients tends to stabilization. Patients with longer therapeutic delay (≥1 year) showed worse VA. Complete resolution of SRF was noted in 71. 4% of cCSCR and 83. 3% of PCV patients. The shorter the referral delay, the better the resolution rate (76. 9% < 1 year vs 61. 5% if ≥1 year). One third of patients required retreatment, superior if longer delay (26. 9% if
Semantics
| Type | Source | Name |
|---|---|---|
| disease | MESH | COVID19 |
| drug | DRUGBANK | Verteporfin |
| disease | MESH | central serous chorioretinopathy |
| disease | MESH | polypoidal choroidal vasculopathy |
| drug | DRUGBANK | Penciclovir |
| drug | DRUGBANK | Tropicamide |